Investigational drug · Phase 2
AZD4635
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Carcinoma, Non-Small-Cell Lung.
Phase 2Last checked: Nov 19, 2026Latest source record: Sep 23, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
7
Any phase or sponsor naming "AZD4635"
First trial start
2018
May 8, 2018
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "AZD4635", any sponsor or status.
Conditions studied
As listed on its trial records.
- Carcinoma, Non-Small-Cell Lung
Approved drugs for the same conditions: Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "AZD4635" as an intervention, largest first.
AstraZenecaAstraZeneca (AZN)
NCT02740985 · 313 participants · Start Jun 17, 2016 · Primary completion Dec 31, 2020
Drug: AZD4635; Durvalumab and 4 more · For: Advanced Solid Malignancies; Non-Small Cell Lung Cancer (NSCLC); Metastatic Castrate-Resistant Prostate Carcinoma (mCRPC) and 1 more
Sites: Fayetteville, Arkansas; Fresno, California; Denver, Colorado · 17 sites in all
AstraZenecaAstraZeneca (AZN)
NCT04089553 · 59 participants · Start Aug 29, 2019 · Primary completion Jun 16, 2021
Drug: AZD4635; Oleclumab and 1 more · For: Prostate Cancer; Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Sites: Denver, Colorado; Fort Myers, Florida; St. Petersburg, Florida · 9 sites in all
- Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination StudyActive, not recruiting
MedImmune LLCAstraZeneca (AZN)
NCT03381274 · 43 participants · Start May 8, 2018 · Primary completion May 24, 2021
Drug: Oleclumab; Osimertinib and 1 more · For: Carcinoma, Non-Small-Cell Lung
Sites: La Jolla, California; San Francisco, California; Aurora, Colorado · 13 sites in all
- A Study of AZD4635 With Durvalumab and With Cabazitaxel and Durvalumab in Patients With mCRPC.Completed
AstraZenecaAstraZeneca (AZN)
NCT04495179 · 30 participants · Start Aug 4, 2020 · Primary completion Nov 1, 2021
Drug: AZD4635; Durvalumab and 1 more · For: Progressive Metastatic Castrate-Resistant Prostate Cancer
Sites: Sacramento, California; Tampa, Florida; Atlanta, Georgia · 16 sites in all
AstraZenecaAstraZeneca (AZN)
NCT04478513 · 28 participants · Start Jul 21, 2020 · Primary completion Dec 23, 2020
Drug: AZD4635; Fluvoxamine · For: Healthy Volunteer/DDI Study
Sites: Harrow, United Kingdom
AstraZenecaAstraZeneca (AZN)
NCT03710434 · 21 participants · Start Nov 1, 2018 · Primary completion Apr 2, 2019
Drug: AZD4635 50 mg nano-suspension (reference); AZD4635 solid oral formulation - fasted and 5 more · For: Healthy Volunteers
Sites: Ruddington, United Kingdom
AstraZenecaAstraZeneca (AZN)
NCT03980821 · 10 participants · Start Jul 4, 2019 · Primary completion Sep 7, 2020
Drug: AZD4635 · For: Advanced Solid Malignancies
Sites: Chūōku, Japan; Kashiwa, Japan
Newest research
PubMed records naming it or its code names, newest first.
- AZD4635 Targets cAMP/CREB Axis to Salvage PARPi-Induced Immune Evasion and Enhance Antitumor Efficacy in Ovarian Cancer.
Pan B, Yang X, Wang X, et al. · Pharmaceutics 2026
- Chirality-Guided Optimization of A2A Adenosine Receptor Antagonists for Enhanced Metabolic Stability and Antitumor Efficacy.
Ding W, Liu S, Liu W, et al. · J Med Chem 2025
- Interaction of Purine and its Derivatives with A1, A2-Adenosine Receptors and Vascular Endothelial Growth Factor Receptor-1 (Vegf-R1) as a Therapeutic Alternative to Treat Cancer.
Figueroa L, Rosas M, Alvarez M, et al. · Drug Res (Stuttg) 2024
- A phase II study (AARDVARC) of AZD4635 in combination with durvalumab and cabazitaxel in patients with progressive, metastatic, castration-resistant prostate cancer.
Alonso-Gordoa T, Goodman M, Vulsteke C, et al. · ESMO Open 2024
- Safety and pharmacokinetics of imaradenant (AZD4635) in Japanese patients with advanced solid malignancies: a phase I, open-label study.
Matsubara N, Kusuhara S, Yamamoto N, et al. · Cancer Chemother Pharmacol 2024
- A phase 2 study of AZD4635 in combination with durvalumab or oleclumab in patients with metastatic castration-resistant prostate cancer.
Falchook GS, Reeves J, Gandhi S, et al. · Cancer Immunol Immunother 2024
Also in development for Carcinoma, Non-Small-Cell Lung
- AdebrelimabSHR-8068, HRS -4642Phase 341 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Non-small Cell Lung Cancer, Advanced or Metastatic Non-small Cell Lung Cancer, Advanced Solid Tumors
- I-DXdDS-7300a, MK-2400Phase 317 trials
Merck & Co. · Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Esophageal Squamous Cell Carcinoma
- Intismeran autogeneV940, mRNA-4157Phase 310 trials
Merck & Co. · Non-small Cell Lung Cancer, Melanoma, Bladder Cancer
- CetrelimabJNJ-63723283Phase 38 trials
Johnson & Johnson (Janssen) · Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Neoplasms
- OleclumabMEDI9447Phase 37 trials
AstraZeneca · Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer, Metastatic Microsatellite-stable Colorectal Cancer
- OlomorasibLY3537982Phase 36 trials
Eli Lilly · Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Neoplasm Metastasis
- NavlimetostatBMS-986504, MRTX1719Phase 34 trials
Bristol Myers Squibb · Pancreatic Ductal Adenocarcinoma, Metastatic Non-small Cell Lung Cancer With MTAP Deletion, Solid Tumors
- Sigvotatug VedotinSGN-B6A, PF-08046047Phase 33 trials
Pfizer · Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from AstraZeneca.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.